InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Subject Dosing in Human Pilot Study #3 Evaluating Oral DehydraTECH-Processed Tirzepatide
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, announced Wednesday morning that dosing has begun for human pilot study #3. The study aims to investigate a DehydraTECH-processed version of Zepbound(R) (tirzepatide), the dual action glucagon-like peptide (“GLP-1”) + glucose-dependent insulinotropic peptide (“GIP”), in oral dose format. The study will involve up to 10 healthy volunteers, with tolerability (side effects), blood absorption…